ADAR1 Capital Management LLC Cuts Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

ADAR1 Capital Management LLC reduced its stake in Silence Therapeutics plc (NASDAQ:SLN) by 55.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,000 shares of the company’s stock after selling 22,290 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Silence Therapeutics were worth $124,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. JPMorgan Chase & Co. bought a new stake in shares of Silence Therapeutics in the 4th quarter worth $26,000. GAMMA Investing LLC lifted its position in shares of Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Silence Therapeutics during the fourth quarter worth about $69,000. FNY Investment Advisers LLC bought a new stake in Silence Therapeutics in the 4th quarter worth about $120,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Silence Therapeutics in the 4th quarter valued at about $134,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SLN. BMO Capital Markets cut their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. Chardan Capital restated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Morgan Stanley lowered their target price on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. The Goldman Sachs Group reduced their price target on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research report on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 7th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.67.

Silence Therapeutics Stock Performance

SLN stock opened at $2.38 on Tuesday. The stock has a fifty day moving average of $4.31 and a 200-day moving average of $9.13. Silence Therapeutics plc has a fifty-two week low of $2.35 and a fifty-two week high of $24.38. The company has a market capitalization of $71.23 million, a price-to-earnings ratio of -1.52 and a beta of 1.25.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.